PharmAlliance International Labs: Elevating Neurological Care Product Leaflet:

Introduction:Welcome to PharmAlliance International Labs Private Limited, your partner in advancing neurological health through cutting-edge pharmaceutical solutions. We are thrilled to unveil our Nimodipine Range, a testament to our unwavering commitment to innovation and patient-centric care. Crafted with precision and backed by scientific rigor, our nimodipine tablets stand as a beacon of hope for individuals navigating the complexities of subarachnoid hemorrhage and its aftermath.

Drug Classification:
Nimodipine, the cornerstone of our latest pharmaceutical innovation, belongs to the esteemed class of medications known as calcium channel blockers. Renowned for their vasodilatory properties, calcium channel blockers exert their therapeutic effects by relaxing and widening blood vessels in the brain. Nimodipine, in particular, enhances cerebral blood flow and oxygen delivery, offering targeted relief in the aftermath of subarachnoid hemorrhage.

Formulations:
Our Nimodipine Range is meticulously formulated in tablet form, with each tablet containing 30 mg of nimodipine. This precise formulation ensures optimal dosing accuracy, empowering healthcare professionals to deliver tailored therapeutic interventions with confidence and efficacy.

Indications:
Nimodipine emerges as a pivotal therapeutic agent in the prevention and treatment of vasospasm following subarachnoid hemorrhage. As a type of stroke characterized by bleeding into the space surrounding the brain, subarachnoid hemorrhage poses significant challenges to neurological function. Nimodipine’s vasodilatory properties mitigate the risk of vasospasm, safeguarding cerebral perfusion and mitigating the risk of secondary ischemic injury.

Usage:
Our nimodipine tablets are designed for oral administration, offering unparalleled convenience and ease of use for patients and healthcare professionals alike. Each tablet should be taken as directed by a healthcare provider, with adherence to prescribed dosage and frequency paramount to achieving optimal therapeutic outcomes.

Dosage:
The recommended dosage regimen for nimodipine tablets typically entails administration of 60 mg every four hours for a duration of 21 consecutive days. However, dosage adjustments may be warranted based on individual patient response, tolerability, and clinical considerations. Healthcare professionals are encouraged to exercise prudence and vigilance in tailoring dosage regimens to meet the unique needs of each patient.

Side Effects:
While nimodipine is generally well-tolerated, a subset of individuals may experience transient side effects such as dizziness, headache, flushing, nausea, and hypotension. Prompt reporting of adverse reactions to healthcare providers facilitates timely intervention and optimization of therapeutic management strategies.

Packaging Specifications:
Our Nimodipine Tablets are thoughtfully packaged in blister packs containing 10 tablets each. This streamlined packaging format not only ensures product integrity and stability but also enhances convenience and portability for patients, facilitating seamless integration into their daily routines.

At PharmAlliance International Labs, we remain steadfast in our commitment to revolutionizing neurological care through innovation, compassion, and scientific excellence. For more information on our Nimodipine Range and other groundbreaking pharmaceutical offerings, please visit our website or consult with your healthcare provider. Your neurological well-being is our utmost priority, driving us to deliver transformative solutions and empower lives.